The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Risk-Treatment Mismatch in the Pharmacotherapy of Heart Failure
Abstract
CONTEXT: Patients with heart failure have a wide spectrum of mortality risks. To maximize the benefit of available pharmacotherapies, patients with high mortality risk should receive high rates of drug therapy. OBJECTIVE: To examine patterns of drug therapy and underlying mortality risk in patients with heart failure. DESIGN, SETTING, AND PATIENTS: In the Enhanced Feedback for Effective Cardiac Treatment (EFFECT) population-based cohort (1999-2001) of 9942 patients with heart failure hospitalized in Ontario, Canada, we evaluated 1418 patients with documented left ventricular ejection fraction of 40% or less and aged 79 years or younger with low-, average-, and high-predicted risk of death within 1 year; all patients survived to hospital discharge. Administration of angiotensin-converting enzyme (ACE) inhibitors, ACE inhibitors or angiotensin II receptor blockers (ARBs), and beta-adrenoreceptor antagonists was evaluated according to predicted risk of death. MAIN OUTCOME MEASURE: Heart failure drug administration rates at time of discharge and 90 days after hospital discharge. RESULTS: At hospital discharge, prescription rates for patients in the low-, average-, and high-risk groups were 81%, 73%, 60%, respectively, for ACE inhibitors; 86%, 80%, 65%, respectively, for ACE inhibitors or ARBs; and 40%, 33%, 24%, respectively, for beta-adrenoreceptor antagonists (all P<.001 for trend). Within 90 days following hospital discharge, the rates were 83%, 76%, and 61% for ACE inhibitors; 89%, 83%, and 67% for ACE inhibitors or ARBs; and 43%, 36%, and 28% for beta-adrenoreceptor antagonists for the 3 risk groups, respectively (all P<.001 for trend). The pattern of lower rates of drug administration in those patients at increasing risk was maintained up to 1 year postdischarge (P<.001). After accounting for varying survival time and potential contraindications to therapy, low-risk patients were more likely to receive ACE inhibitors or ARBs (adjusted hazard ratio [HR], 1.61; 95% confidence interval [CI], 1.49-1.74) and beta-adrenoreceptor antagonists (HR, 1.80; 95% CI, 1.60-2.01) compared with high-risk patients (both P<.001). CONCLUSIONS: Patients with heart failure at greatest risk of death are least likely to receive ACE inhibitors, ACE inhibitors or ARBs, and beta-adrenoreceptor antagonists. Understanding the reasons underlying this mismatch may facilitate improvements in care and outcomes for patients with heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Fundamentals of Biostatistics.
(1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-70-4-873 · Cited by 4,575
Swedberg, K., & Kjekshus, J. (1988) · The American Journal of Cardiology · doi:10.1016/s0002-9149(88)80087-0 · Cited by 3,762
(1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271003 · Cited by 3,725
Writing Group Members, Thom, T., Haase, N., Rosamond, W., Howard, V. J., Rumsfeld, J., Manolio, T., Zheng, Z.-J., Flegal, K., O’Donnell, C., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.171600 · Cited by 3,451
The natural history of congestive heart failure: the Framingham study
McKee, P. A., Castelli, W. P., McNamara, P. M., & Kannel, W. B. (1971) · New England Journal of Medicine · doi:10.1056/nejm197112232852601 · Cited by 3,448
Garg, R. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520420066040 · Cited by 1,771
Fonarow, G. C. (2005) · JAMA · doi:10.1001/jama.293.5.572 · Cited by 1,611
Flather, M. D., Yusuf, S., Køber, L., Pfeffer, M., Hall, A., Murray, G., Torp-Pedersen, C., Ball, S., Pogue, J., Moyé, L., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02212-1 · Cited by 1,585
Permutation Tests: A Practical Guide to Resampling Methods for Testing Hypotheses
Niknian, M. (1995) · Technometrics · doi:10.1080/00401706.1995.10484341 · Cited by 1,462
Committee Members, Hunt, S. A., Baker, D. W., Chin, M. H., Cinquegrani, M. P., Feldmanmd, A. M., Francis, G. S., Ganiats, T. G., Goldstein, S., Gregoratos, G., et al. (2001) · Circulation · doi:10.1161/hc4901.102568 · Cited by 1,442
Komajda, M. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00700-5 · Cited by 1,222
Alter, D. A., Naylor, C. D., Austin, P., & Tu, J. V. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910283411806 · Cited by 678
The Treatment of Unrelated Disorders in Patients with Chronic Medical Diseases
Redelmeier, D. A., Tan, S. H., & Booth, G. L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805213382106 · Cited by 635
Bhatt, D. L., Roe, M. T., Peterson, E. D., Li, Y., Chen, A. Y., Harrington, R. A., Greenbaum, A. B., Berger, P. B., Cannon, C. P., Cohen, D. J., et al. (2004) · JAMA · doi:10.1001/jama.292.17.2096 · Cited by 568
MacIntyre, K., Capewell, S., Stewart, S., Chalmers, J. W. T., Boyd, J., Finlayson, A., Redpath, A., Pell, J. P., & McMurray, J. J. V. (2000) · Circulation · doi:10.1161/01.cir.102.10.1126 · Cited by 553
Lee, W. H., & Packer, M. (1986) · Circulation · doi:10.1161/01.cir.73.2.257 · Cited by 552
Lipid-Lowering Therapy With Statins in High-Risk Elderly Patients: The Treatment-Risk Paradox
Ko, D. T., Mamdani, M., & Alter, D. A. (2004) · JAMA · doi:10.1001/jama.291.15.1864 · Cited by 412
β-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis
Brophy, J. M., Joseph, L., & Rouleau, J. L. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-7-200104030-00008 · Cited by 389 · cited 1×
“The median number (interquartile range) of cardiovascular prescription drugs was similar across risk categories (4 [3-6] in lowrisk, 5 [3-6] in average-risk, and 4 [3-6] in high-risk groups).”
BackgroundHLee, W., & MPacker (1986) · Circulation · Cited by 365
Stone, P. H. (1996) · JAMA · doi:10.1001/jama.275.14.1104 · Cited by 361
Permutation Tests: A Practical Guide to Resampling Methods for Testing Hypotheses.
Modarres, R., & Good, P. (1995) · Journal of the American Statistical Association · doi:10.2307/2291167 · Cited by 328
Krum, H., Roecker, E. B., Mohacsi, P., Rouleau, J. L., Tendera, M., Coats, A. J. S., Katus, H. A., Fowler, M. B., Packer, M., & for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group (2003) · JAMA · doi:10.1001/jama.289.6.712 · Cited by 310
Schechter, D. C. (1969) · Diseases of the Chest · doi:10.1016/s0096-0217(16)31665-x · Cited by 301
Califf, R. M., Armstrong, P. W., Carver, J. R., D'Agostino, R. B., & Strauss, W. E. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(96)87733-3 · Cited by 257
Masoudi, F. A., Rathore, S. S., Wang, Y., Havranek, E. P., Curtis, J. P., Foody, J. M., & Krumholz, H. M. (2004) · Circulation · doi:10.1161/01.cir.0000138934.28340.ed · Cited by 176
Shibata, M. C., Flather, M. D., & Wang, D. (2001) · European Journal of Heart Failure · doi:10.1016/s1388-9842(01)00144-1 · Cited by 173
Thrombolytic Therapy for Eligible Elderly Patients With Acute Myocardial Infarction
Krumholz, H. M. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540450039032 · Cited by 167
Rouleau, J. L., Roecker, E. B., Tendera, M., Mohaçsi, P., Krum, H., Katus, H. A., Fowler, M. B., Coats, A. J. S., Castaigne, A., Scherhag, A. W., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.11.037 · Cited by 163
Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials
Jong, P., Demers, C., McKelvie, R. S., & Liu, P. P. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01775-2 · Cited by 162
Stukel, T. A., Lucas, F. L., & Wennberg, D. E. (2005) · JAMA · doi:10.1001/jama.293.11.1329 · Cited by 158
Tu, J. V., Austin, P. C., & Chan, B. T. (2001) · JAMA · doi:10.1001/jama.285.24.3116 · Cited by 157
Lee, D. S., Austin, P. C., Rouleau, J. L., Liu, P. P., Naimark, D. M. J., & Tu, J. V. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2003.12.040 · Cited by 149
Self-citationSin, D. D., & McAlister, F. A. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01346-3 · Cited by 143
How should age affect management of acute myocardial infarction? A prospective cohort study
Barakat, K., Wilkinson, P., Deaner, A., Fluck, D. S., Ranjadayalan, K., & Timmis, A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07114-1 · Cited by 125
Morris, A. D., Boyle, D. I., McMahon, A. D., Pearce, H., Evans, J. M. M., Newton, R. W., Jung, R. T., MacDonald, T. M., & The Darts/Memo Collaboration (1997) · Diabetes Care · doi:10.2337/diacare.20.9.1363 · Cited by 109
Fonarow, G. C., Adams, K. F., Abraham, W. T., Yancy, C. W., & Boscardin, W. J. (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2005.02.073 · Cited by 108
Gambassi, G., Lapane, K. L., Sgadari, A., Carbonin, P., Gatsonis, C., Lipsitz, L. A., Mor, V., & Bernabei, R. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.1.53 · Cited by 108
DEEDWANIA, P. C., Gottlieb, S., Ghali, J. K., Waagstein, F., & Wikstrand, J. C. M. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.05.022 · Cited by 108
Kotlyar, E., KEOGH, A. M., Macdonald, P. S., Arnold, R. H., McCaffrey, D. J., & Glanville, A. R. (2002) · The Journal of Heart and Lung Transplantation · doi:10.1016/s1053-2498(02)00459-x · Cited by 99
Ahmed, A., Kiefe, C. I., Allman, R. M., Sims, R. V., & DeLong, J. F. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50457.x · Cited by 97
Age, risk-benefit trade-offs, and the projected effects of evidence-based therapies
Alter, D. A., Manuel, D. G., Gunraj, N., Anderson, G., Naylor, C. D., & Laupacis, A. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.10.039 · Cited by 90
Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study
Tonkin, A. M., Colquhoun, D., Emberson, J., Hague, W. E., KEECH, A. C., Lane, G., MacMahon, S. W., Simes, R. J., Thompson, P. L., White, H. D., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03257-8 · Cited by 87
CCORT/CCS quality indicators for congestive heart failure care.
Lee, D. S., Tran, C., Flintoft, V. F., Grant, F., Liu, P. P., & Tu, J. V. (2003) · PubMed · Cited by 76
Self-citationHalon, D. A., Adawi, S., Dobrecky‐Mery, I., & Lewis, B. S. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.08.044 · Cited by 75
Rochon, P. A., Tu, J. V., Anderson, G. M., Gurwitz, J. H., Clark, J., Lau, P., Szalai, J. P., Sykora, K., & Naylor, C. D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02606-4 · Cited by 73
Determinants of Mortality in Elderly Patients With Heart Failure
Havranek, E. P., Abrams, F. R., Stevens, E. R., & Parker, K. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.18.2024 · Cited by 71
Liu, P. X., Arnold, J. M. O., Belenkie, I., Demers, C., Dorian, P., Giannetti, N., Haddad, H. A., Howlett, J. G., Ignazewski, A., Jong, P., et al. (2003) · PubMed · Cited by 69
Johnson, D., Jin, Y., Quan, H., & C̆ujec, B. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)01058-1 · Cited by 65
McMurray, J. J. V. (1998) · PubMed · Cited by 59
Bhatt, D. L., Roe, M. T., & Peterson, E. D. (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.12.104 · Cited by 53
Smith, N. L., Chan, J. D., Rea, T. D., Wiggins, K. L., Gottdiener, J. S., Lumley, T., & Psaty, B. M. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.04.002 · Cited by 44
Lipid-lowering therapy with statins in high-risk elderly patients. The treatment-risk paradox
Ko, D. T., Mamdani, M., & Alter, D. A. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.06.019 · Cited by 30
Beta-Blocker Benefit According to Severity of Heart Failure
Bouzamondo, A., Hulot, J., Sanchez-Peña, P., & Lechat, P. P. (2003) · European Journal of Heart Failure · doi:10.1016/s1388-9842(03)00042-4 · Cited by 30
Task force 2. Clinical epidemiology: The conceptual basis for interpreting risk factors
Furberg, C. D., Hennekens, C. H., Hulley, S. B., Manolio, T. A., Psaty, B. M., & Whelton, P. K. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(96)87730-8 · Cited by 21
Krum, H., Roecker, E. B., & Mohaçsi, P. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(03)00173-9 · Cited by 20
Cited by
Austin, P. C. (2014) · Statistics in Medicine · doi:10.1002/sim.5984 · Cited by 1,422
Stukel, T. A., Fisher, E. S., Wennberg, D. E., Alter, D. A., Gottlieb, D. J., & Vermeulen, M. J. (2007) · JAMA · doi:10.1001/jama.297.3.278 · Cited by 786
Interventions to improve the appropriate use of polypharmacy for older people
Patterson, S. M., Cadogan, C. A., Kerse, N., Cardwell, C. R., Bradley, M. C., Ryan, C., & Hughes, C. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008165.pub3 · Cited by 754
Lee, D. S., Gona, P., Vasan, R. S., Larson, M. G., Benjamin, E. J., Wang, T. J., Tu, J. V., & Levy, D. (2009) · Circulation · doi:10.1161/circulationaha.108.815944 · Cited by 672
Self-citationKotecha, D., Holmes, J., Krum, H., Altman, D. G., Manzano, L., Cleland, J. G. F., Lip, G. Y. H., Coats, A. J. S., Andersson, B., Kirchhof, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61373-8 · Cited by 579
Metadata
- Authors
- Lee, D. S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2005-09-14
- Volume
- 294
- Issue
- 10
- Pages
- 1240
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2074192941
- Cited by
- 257
- References
- 57
- FWCI
- 14.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.